STUDI PENANGANAN ANEMIA PADA PASIEN GAGAL GINJAL KRONIK DAN PENGARUHNYA TERHADAP KUALITAS HIDUP DI UNIT HEMODIALISIS RSUD CIBABAT CIMAHI

• Main Author: Yasinta Dewi Nurhasanah, Cut
• Format: Final Project
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/44143
• Institution: Institut Teknologi Bandung

Chronic kidney disease is a condition of progressive kidney damage which is characterized with reduction of glomerulus filtration rate <60 mL/menit/1,73 m2 for about 3 months. Anemia is a common complication disease in chronic kidney disease which happens to 80 -90% to the patient of chronic kidney disease. It has been found that anemia happens to all of the hemodialysis patient with CKD in RSUD Cibabat, Cimahi, from 2018 –2019. Anemia can be treated with eritropoeitin, iron, and blood transfusion. The decrease of hemoglobin level in anemia has a correlation with quality of life of the patients. The purpose of this study is to determine the accuracy of antianemia therapy, outcome of the therapy and the correlation of hemoglobin level with quality of life of the patient in RSUD Cibabat. This is cross sectional study with descriptive quantitative method using retrospective and concurrent method from medical records and interview by using EQ-5D-3L questionnaire. Quality of life will be analyzed with value set of EQ-5D-3L. Total of the sample obtained was 62 respondents based on total sampling which corresponds to inclusion criteria from March –July 2019. 99,94% of patients start to get EPO when Hb ?10 g/dL. Only 11,29% of patients starts using EPO when blood pressure is <180/<110 mmHg. All patients in correction phase group didn’t get the right dose and frequency of EPO meanwhile patients in maintenance phase group get the right dose and frequency. 58,06% of the patients received blood transfusion which is categorized by Pernefri 2011. All the patients (100%) get folic acid as adjuvant therapy for anemia in CKD. Only 8,06% of the patients has reached Hb level > 10 g/dL. From November to January, 29,03% patients most likely has reached the responds target of EPO which is to increase Hb 1 to 2 g/dL per month. There is a low correlation between Hb level and quality of life (r=0,286). The highest average utility of the patient chronic kidney disease with anemia in hemoglobin level range in 8 –9,4 g/dL which is 0,550 ± 0,38 dan EQ-VAS 57,25 ± 19,90.